Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eveotox for Moderate to Severe Glabellar Lines
NCT06937944Phase 3Recruiting
- Sponsor
- Junhemeng Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of JHM03 in glabellar lines (3 arms), sponsored by Junhemeng Biopharmaceutical. Primary endpoint: Primary Outcome Measure at 4 weeks. Started Apr 2025; status: recruiting.
02
Drugs
JHM03
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06937944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937944.